Wyeth opts for price point differentiation approach with proton pump inhibitor pantoprazole, launching at a 28% discount to AstraZeneca's Prilosec (omeprazole) -$3 AWP per 40 mg tablet versus $4.14 per 20 mg tablet. Wyeth told the financial community that it did not intend to launch Protonix until both the oral and I.V. formulations were approved. The company said that the I.V. formulation should be approved by early in the third quarter. Protonix will be the fourth entrant in the PPI class. The discounting strategy is similar to that employed by the fourth entrant in the statin cholesterol reduction class, Novartis' Lescol
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth